Advertisement
Therapeutics clinic

Navigating the new diabetes drugs: cardiovascular benefits and when to use

NAOMI SZWARCBARD, Sophia Zoungas

Figures

© FERTNIG/ISTOCKPHOTO.COM
© FERTNIG/ISTOCKPHOTO.COM

Abstract

The recent introduction of antihyperglycaemic medications that not only improve glycated haemoglobin (HbA1c) levels but also provide cardiovascular, renal and overall mortality benefit renews hope for better management of diabetes. The new sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are potential game changers for people with type 2 diabetes.

Article Extract

Diabetes is a major contributor to morbidity and mortality among people in Australia. An estimated 1.2 million (6%) Australian adults have been diagnosed with diabetes, with about 85% having type 2 diabetes.1 Diabetes results in more than one million hospitalisations annually and contributes to about 10% of the 160,000 deaths in Australia each year, and these numbers are rising.1,2 Improved glycaemic control in people with type 2 diabetes aims to prevent complications such as stroke, acute myocardial infarction, heart failure, amputation, end-stage kidney disease and blindness.

Figures

© FERTNIG/ISTOCKPHOTO.COM
© FERTNIG/ISTOCKPHOTO.COM